StockNews.com Lowers InfuSystem (NYSE:INFU) to Buy

StockNews.com downgraded shares of InfuSystem (NYSE:INFU) from a strong-buy rating to a buy rating in a research note released on Saturday.

Separately, B. Riley initiated coverage on InfuSystem in a report on Thursday, September 26th. They set a buy rating and a $13.00 price objective on the stock.

InfuSystem Price Performance

InfuSystem stock opened at $6.70 on Friday. The company has a quick ratio of 1.64, a current ratio of 2.07 and a debt-to-equity ratio of 0.64. The firm has a market cap of $142.68 million, a price-to-earnings ratio of -670,000.00 and a beta of 1.46. InfuSystem has a fifty-two week low of $5.74 and a fifty-two week high of $10.99.

InfuSystem (NYSE:INFU) last released its quarterly earnings results on Thursday, August 8th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.01). The company had revenue of $33.70 million for the quarter. InfuSystem had a return on equity of 0.70% and a net margin of 0.28%.

Institutional Investors Weigh In On InfuSystem

Several hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its holdings in InfuSystem by 1.7% in the first quarter. Vanguard Group Inc. now owns 1,083,730 shares of the company’s stock valued at $9,288,000 after acquiring an additional 18,432 shares during the last quarter. Sequoia Financial Advisors LLC purchased a new stake in shares of InfuSystem during the second quarter worth about $272,000. Wasatch Advisors LP increased its position in shares of InfuSystem by 3.4% during the fourth quarter. Wasatch Advisors LP now owns 846,609 shares of the company’s stock worth $8,923,000 after acquiring an additional 27,881 shares during the last quarter. Ranger Investment Management L.P. increased its position in shares of InfuSystem by 4.7% during the fourth quarter. Ranger Investment Management L.P. now owns 689,842 shares of the company’s stock worth $7,271,000 after acquiring an additional 30,835 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of InfuSystem by 6.1% during the second quarter. Bank of New York Mellon Corp now owns 93,899 shares of the company’s stock worth $641,000 after acquiring an additional 5,391 shares during the last quarter. Institutional investors and hedge funds own 71.13% of the company’s stock.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.